BridgeMD
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
EU CTIS ID: 2025-522883-34-00
What this study is testing
To evaluate the PFS at 12 months and compare to the historical PFS of the KEYNOTE-826 trial.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Inclusion criteria for the observation cohort: Persistent, recurrent, or metastatic cervical cancer commencing treatment or currently treated with a pembrolizumab containing regimen.
- Inclusion criteria for the early discontinuation cohort: • Previous inclusion in the observation cohort • Choice made to stop pembrolizumab for one of the following reasons: o Confirmed complete response if they had received at least 8 cycles of 3- weekly pembrolizumab, including at least 9 weeks beyond a CR (consistent with KEYNOTE-826 criteria) OR o Immune-related toxicity grade ≥ 3 OR o Patient’s preference (e.g. chronic or invalidating grade 1-2 immune-related toxicity) OR o Confirmed partial response if they had received at least 8 cycles of 3- weekly pembrolizumab, including at least 9 weeks beyond a PR (timing consistent with KEYNOTE-826 criteria) • Eligible and willing to discontinue pembrolizumab (with or without discontinuing bevacizumab)
You likely can't join if
- Malignant other disease other than cervical carcinoma that required active treatment in the past 2 years: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or any carcinoma in situ that have undergone potentially curative therapy are not excluded
- Any condition, in opinion of the investigator, that may hamper compliance to the study procedures.
- Insufficient proficiency in written and spoken Dutch to understand the study information, complete Dutch language questionnaires, or provide informed consent will be excluded
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.